Sprint Bioscience

Building value in drug development

  • CEO: Anders Åberg
  • First investment year: 2010
  • Fund: Stockholm
  • Business sector: Life Science
Sprint Bioscience

Sprint Bioscience develops pharmaceuticals in the areas of cancer and metabolism working with a broad portfolio of projects into the preclinical stage. The goal is to enter into commercial partnerships with larger pharmaceutical companies at an early phase.